Advancing risk stratification for DSP cardiomyopathy with postmortem genetic testing

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Both DSP cardiomyopathy and plakophilin 2 are associated with arrhythmogenic right ventricular cardiomyopathies via a desmosomal mechanism.

Once-Weekly Pediatric Growth Hormone Snags FDA Approval

The FDA approved long-acting injectable somatrogon (Ngenla) for pediatric human growth hormone deficiency, developers Pfizer and OPKO Health announced this week. Somatrogon is indicated for

July 1, 2023

Qigong shows promise in reducing chronic back pain in veterans

Chronic pain is widespread in the United States, particularly among military veterans, affecting between 40 to 70% of this population and serving as a leading

January 17, 2025

Antengene’s multiple myeloma therapy approved in Hong Kong

Xpovio plus dexamethasone is indicated for relapsed and/or refractory multiple myeloma. Credit: Nemes Laszlo / Shutterstock.com. Antengene has received approval from the Department of Health,

July 17, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.